Hello world!

by AdoloreJTC24 | Feb 7, 2024 | Uncategorized

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting

by AdoloreJTC24 | Jan 30, 2024 | Press Releases

DELRAY BEACH, FL / January 30, 2024 / Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roy C. Levitt, MD,...

Adolore BioTherapeutics Presents Promising Preclinical Data Supporting Its Innovative Gene Therapy to Treat Chronic Pain

by AdoloreJTC24 | Dec 5, 2023 | Press Releases

Innovative rdHSV-based CA8* gene therapy demonstrates preclinical proof-of-concept as a disease-modifying long-acting local analgesic to replace opioids in chronic osteoarthritis (OA) knee pain managementDELRAY BEACH, FL / December 5, 2023 / Adolore BioTherapeutics...

Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference

by AdoloreJTC24 | Oct 11, 2023 | Press Releases

Live moderated webcast with Roelof Rongen, Chief Executive Officer of Adolore BioTherapeutics on Wednesday, October 25th at 3:00 PM ETDELRAY BEACH, FL / October 11, 2023 / Adolore BioTherapeutics (“Adolore” or the “Company”), a company focused...

NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain

by AdoloreJTC24 | Oct 3, 2023 | Press Releases

UH3 Award follows the successful completion of an initial NIH/NINDS HEAL UG3 grant for which all pre-clinical milestones were metThis NIH/NINDS HEAL UH3 Award will support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study in patients,...